Tempus acquires AI pathology firm Paige for $81.25 million

CHICAGO - Tempus AI, Inc. (NASDAQ:TEM), a $12.8 billion healthcare technology company showing impressive revenue growth of nearly 60% over the last twelve months, announced Friday it has acquired Paige, an AI company specializing in digital pathology, for $81.25 million. The deal will be paid predominantly in Tempus common stock, with Tempus also assuming Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement. According to InvestingPro data, Tempus operates with a moderate level of debt and maintains a healthy current ratio of 1.54.

The acquisition provides Tempus access to Paige’s dataset of nearly 7 million digitized pathology slide images with associated clinical and molecular data. This collection spans 45 countries and includes diverse demographic information, according to the company’s press release. The deal comes as Tempus’s stock has shown strong momentum, with a year-to-date return of 127% and trading near its 52-week high of $91.45.

Paige, founded in 2017, developed the first FDA-cleared AI application in pathology, which helps researchers and pathologists better detect cancer. The company has also created what it describes as the first million-slide foundation model for cancer.

"As we embark upon building the largest foundation model that’s ever been built in oncology, the acquisition of Paige substantially accelerates our efforts," said Eric Lefkofsky, Founder and CEO of Tempus. Five analysts have recently revised their earnings expectations upward for the upcoming period, as revealed by InvestingPro analysis, suggesting growing confidence in the company’s strategic direction.

Razik Yousfi, CEO and CTO of Paige, stated that joining Tempus will allow the company to bring its innovations to a broader patient population.

Tempus, which focuses on advancing precision medicine through AI applications in healthcare, aims to integrate Paige’s technology into its existing operations. The company maintains one of the world’s largest libraries of multimodal healthcare data, according to the announcement.

The acquisition is expected to strengthen Tempus’s position in digital pathology while expanding its dataset and technical team capabilities. Get deeper insights into Tempus’s financial health, growth prospects, and 5+ additional ProTips with a subscription to InvestingPro, including exclusive access to comprehensive Pro Research Reports covering 1,400+ top stocks.

In other recent news, Tempus AI Inc. reported its second-quarter 2025 earnings, showcasing results that exceeded expectations. The company’s revenue reached $314.6 million, surpassing the forecast of $297.8 million. Additionally, the earnings per share were reported at -$0.22, compared to the anticipated -$0.25, indicating a narrower-than-expected loss. BTIG responded to Tempus AI’s strong performance by raising its price target for the company to $85.00, up from $75.00, while maintaining a Buy rating. This decision was influenced by a 36% year-over-year growth in data revenue and a 33% increase in core genomics revenue. TD Cowen also increased its price target for Tempus AI to $72.00 from $62.00, citing stronger genomic volumes and a positive outlook for the Ambry business. Meanwhile, Stifel maintained a Hold rating on Tempus AI, keeping its price target at $65.00. These developments reflect a positive sentiment among analysts regarding Tempus AI’s recent performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.